Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS8Q7A)

Drug Name
Ontazolast Drug Info
Synonyms
Ontazolast; UNII-8P8TW6B25I; BIRM-270; 147432-77-7; 8P8TW6B25I; N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine; Ontazolast [USAN:INN]; AC1Q4WID; Ontazolast (USAN/INN); SCHEMBL75875; AC1L2G78; CHEMBL2104845; 2-(((S)-2-Cyclohexyl-1-(2-pyridyl)ethyl)amino)-5-methylbenzoxazole; n-[(1s)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine; D02847; 32254-EP2311827A1; 32254-EP2301933A1; 32254-EP2281815A1; 32254-EP2305640A2; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)-
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Cross-matching ID
PubChem CID
71458
CAS Number
CAS 147432-77-7
TTD Drug ID
DMS8Q7A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Leukotriene receptor (LTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SR-2640 DMFDA4Y Asthma CA23 Phase 2 [3]
PIRODOMAST DMC3T2S Asthma CA23 Phase 2 [4]
WF-11605 DM57FHW Bacterial infection 1A00-1C4Z Phase 1 [5]
SK&F-S-106203 DM2BDAW Asthma CA23 Discontinued in Phase 2 [6]
FK-664 DMFGJNW Cardiac disease BA00-BE2Z Discontinued in Phase 2 [7]
SMP-028 DMQSGOD Asthma CA23 Discontinued in Phase 1 [8]
NZ-107 DMXJO5F Asthma CA23 Discontinued in Phase 1 [9]
ABT-080 DMTYWE9 Asthma CA23 Discontinued in Phase 1 [10]
BAY-Y-1015 DM0UEKF Inflammation 1A00-CA43.1 Discontinued in Phase 1 [11]
ICI-198615 DM0195G Asthma CA23 Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene receptor (LTR) TTTWGIX NOUNIPROTAC Modulator [2]

References

1 A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol. 1999;44(3):259-65.
2 Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64.
3 Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4.
4 Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997-1003.
5 WF11605, an antagonist of leukotriene B4 produced by a fungus. II. Structure determination. J Antibiot (Tokyo). 1992 May;45(5):704-8.
6 Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Pulm Pharmacol. 1991;4(3):177-89.
7 US patent application no. 7,175,854, Pharmaceutical preparation comprising an active dispersed on a matrix.
8 Effect of SMP-028 on steroidogenesis in rats; mechanism of toxicological events on endocrine organs of rats. Toxicol In Vitro. 2014 Apr;28(3):397-402.
9 Effects of NZ-107 on tracheal responses to adenosine in the guinea pig. Jpn J Pharmacol. 1991 May;56(1):79-84.
10 An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010 February; 10(1): 60-66.
11 The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 1996 Mar;39(3):515-21.
12 In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987 Nov;243(2):548-56.